Indian branded-generics and consumer-healthcare maker known for OTC brands like Manforce and Prega News, plus prescription drugs.
Indian branded-generics and consumer-healthcare maker known for OTC brands like Manforce and Prega News, plus prescription drugs.
Sells prescription drugs through a very large force of sales representatives who visit doctors and chemists, and consumer brands such as Manforce condoms and Prega News pregnancy kits through pharmacies and shops. Most sales are in India. The 2024 purchase of Bharat Serums and Vaccines added women's health and critical-care products. The Juneja family are the promoters.
In one line: India's OTC-and-generics hybrid, part Cipla part J&J consumer.
Moat: narrow (brand, distribution). Strong consumer brand recall and one of India's largest pharma field forces.
Headquarters: New Delhi, India · Founded: 1995 · Employees: 27,000
Size Mankind Pharma (MANKIND.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $11.6B, the 106th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,625 on 18 Nov 2026.
Performance Over six months the shares gained 5.3%, against +7.6% for the median peer and +3.8% for the India market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 13.3% over the last twelve months (peer median +14.5%); the operating margin is 20.6% (peer median 20.1%).
Valuation It trades at 44.4× forward earnings against a peer median of 30.9× (5th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 29% a year for seven years (Req g). Recent delivered growth is +18%, so the hurdle is +10 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.5 points above its cost of capital (10.8% WACC).
Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹154B | ₹143B | ₹122B | ₹103B | ₹87.4B |
| Revenue growth | — | +17% | +19% | +17% | — |
| Gross profit | ₹67.9B | ₹56.4B | ₹50.4B | ₹41.2B | ₹33.9B |
| EBITDA | ₹40.8B | ₹36.6B | ₹31.0B | ₹25.6B | ₹19.4B |
| Net income | ₹22.4B | ₹19.1B | ₹19.9B | ₹19.1B | ₹12.8B |
| Free cash flow | n/a | ₹18.9B | ₹19.1B | ₹18.4B | ₹9.96B |
| Capital expenditure | n/a | ₹7.37B | ₹5.31B | ₹3.89B | ₹8.32B |
| Total debt | ₹54.2B | ₹63.1B | ₹85.1B | ₹2.07B | ₹1.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Mankind Pharma MANKIND.NS | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Cipla CIPLA.NS | $12.2B | +1% | -1% | 13% | 29.1× | 28.4% |
| Zydus Lifesciences ZYDUSLIFE.NS | $12.8B | +18% | +24% | 17% | 30.0× | n/a |
| Lupin LUPIN.NS | $9.67B | -14% | +24% | 24% | 21.0× | 8.8% |
| Torrent Pharmaceuticals TORNTPHARM.NS | $18.8B | +3% | +42% | 22% | 70.2× | 37.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MANKIND.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +16.5% | +6.4% | 3rd highest of 21 |
| 6-month return | +5.3% | +7.6% | 11th highest of 21 |
| Distance from 52-week high | -3.0% | -7.6% | 6th highest of 21 |
| Revenue growth (TTM) | +13.3% | +14.5% | 7th lowest of 20 |
| Operating margin | 20.6% | 20.1% | 10th highest of 19 |
| Forward P/E | 44.4× | 30.9× | 5th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 28.6% | 12.4% | 6th most demanding of 15 |
| Growth delivered (Del g) | +18.1% | +11.9% | 4th highest of 15 |
| Hurdle (Req g minus delivered) | +10.5 pp | -11.2 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | +0.5 pp | +3.3 pp | 7th lowest of 19 |
| EV / EBITDA | 27.3× | 17.1× | 5th most expensive of 13 |
| Net debt / EBITDA | 0.7× | 0.3× | 6th most indebted of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mankind Pharma MANKIND.NS | India | $11.6B | +5% | +13% | 21% | 44.4× | 28.6% | +18.1% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $11.6B | -4% | -19% | 19% | 40.7× | 24.9% | +6.8% |
| Recordati REC.MI | Italy | $12.0B | +3% | +8% | 30% | 16.6× | 1.1% | +12.6% |
| Repligen RGEN | United States | $11.0B | +55% | +14% | 9% | 71.0× | 56.9% | +15.0% |
| Sbp 1177.HK | Hong Kong | $12.2B | +5% | +15% | 30% | 17.5× | -5.7% | +5.4% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.5B | +5% | -4% | 9% | 32.0× | 30.7% | +12.1% |
| Zydus Lifesciences ZYDUSLIFE.NS | India | $12.8B | +18% | +24% | 17% | 30.0× | n/a | n/a |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | Hong Kong | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% | +33.6% |
| TG Therapeutics TGTX | United States | $9.99B | +66% | +69% | 21% | 25.2× | 43.0% | +426.7% |
| Laurus Labs LAURUSLABS.NS | India | $13.4B | +73% | +23% | 24% | 76.4× | 51.2% | +7.3% |
| Pharmaron Beijing 300759.SZ | China | $9.90B | +52% | +18% | 14% | 36.8× | n/a | n/a |
| Spyre Therapeutics SYRE | United States | $9.64B | +41% | n/a | n/a | n/a | n/a | n/a |
| Madrigal Pharmaceuticals MDGL | United States | $9.25B | -22% | +93% | -11% | 81.5× | n/a | n/a |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $9.16B | +69% | +9% | 26% | n/a | -6.6% | +6.6% |
| Ipsen IPN.PA | France | $14.8B | +1% | +14% | 30% | 10.8× | -6.7% | +7.2% |
| Sichuan Biokin Pharmaceutical 688506.SS | China | $14.9B | -7% | +14% | -43% | n/a | n/a | n/a |
| Yunnan Baiyao 000538.SZ | China | $15.0B | +11% | +5% | 11% | 18.3× | -0.2% | +4.7% |
| PharmaEssentia 6446.TW | Taiwan | $15.0B | +67% | +78% | 40% | 31.9× | 23.7% | +94.8% |
| Orion ORNAV.HE | Finland | $15.7B | +41% | +34% | 38% | 23.6× | -6.2% | +11.7% |
| Praxis Precision Medicines PRAX | United States | $8.53B | -9% | -100% | n/a | n/a | n/a | n/a |
| Jazz Pharmaceuticals Public JAZZ | United States | $15.9B | +4% | +13% | 25% | 9.3× | -2.8% | +12.5% |